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Background and purpose: Sex and race disparities in recombinant tissue plasminogen
activator (rt-PA) use have been reported. We sought to explore sex and race differences
in the utilization of rt-PA at primary stroke centers (PSCs) compared to non-PSCs across
the US.
Methods: Data from the National (Nationwide) Inpatient Sample (NIS) 2004–2010 was
utilized to assess sex differences in treatment for ischemic stroke in PSCs compared to
non-PSCs.
results: There were 304,152 hospitalizations with a primary diagnosis of ischemic
stroke between 2004 and 2010 in the analysis: 75,160 (24.7%) patients were evaluated at a PSC. A little over half of the patients evaluated at PSCs were female (53.8%).
A lower proportion of women than men received rt-PA at both PSCs (6.8 vs. 7.5%,
p < 0.001) and non-PSCs (2.3 vs. 2.8%, p < 0.001). After adjustment for potential confounders the odds of being treated with rt-PA remained lower for women regardless
of presentation to a PSC (OR 0.87, 95% CI 0.81–0.94) or non-PSC (OR 0.88, 95% CI
0.82–0.94). After stratifying by sex and race, the lowest absolute treatment rates were
observed in black women (4.4% at PSC, 1.9% at non-PSC). The odds of treatment,
relative to white men, was however lowest for white women (PSC OR = 0.85, 95%
CI 0.78–0.93; non-PSC OR = 0.80, 95% CI 0.75–0.85). In the multivariable model,
sex did not modify the effect of PSC certification on rt-PA utilization (p-value for
interaction = 0.58).
conclusion: Women are less likely to receive rt-PA than men at both PSCs and nonPSCs. Absolute treatment rates are lowest in black women, although the relative difference in men and women was greatest for white women.
Keywords: acute stroke care, thrombolysis, health policy, emergency care, healthcare delivery systems
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INTRODUCTION

transferred from other hospitals. Patients who were missing
information on death, sex, length of stay, or primary payer were
excluded. Treatment with IV rt-PA, defined by ICD-9 procedure
code 99.10, was the primary outcome. When compared to pharmacy billing data, this code has been shown to identify 77% of IV
rt-PA cases (23). This study involved the analysis of de-identified
data and was exempt from IRB approval.

Intravenous recombinant tissue plasminogen activator (IV rt-PA)
is a thrombolytic agent that improves outcomes in stroke patients
when administered within 4.5 h of symptom onset (1–3). The
utilization of this therapy in the United States is low despite
consensus guidelines recommending its use (4, 5). Although
patient-level factors, primarily a delay from symptom onset to
emergency department arrival, are a major contributor to the
low utilization of IV rt-PA, provider- and hospital-level factors
may also contribute to underutilization. The Joint Commission
(TJC) primary stroke center (PSC) certification, which requires
an acute stroke team, a stroke unit, and written care protocols,
has been associated with higher rt-PA utilization and lower
mortality among patients when compared to patients treated at
non-PSCs (6–10).
Sex disparities in IV rt-PA use have been reported; however,
whether PSCs reduce these disparities is unknown (11–13).
Given this, an analysis of IV rt-PA treatment comparing nonPSCs and PSCs across the US would fill a gap in our understanding. When compared with men, women have worse functional
outcomes and lower quality of life after stroke (14, 15). While
this may be attributable to patient-level factors, such as older
age at time of stroke or differences in stroke subtype, there is
also evidence that women receive lower quality of care than
men, with less efficient stroke evaluation, delay in treatment
with thrombolytics, and lower adherence to stroke care quality
metrics (16–18).
Further contributing to the sex disparity in IV rt-PA utilization
is evidence that sex differences may vary by race/ethnicity, with
black women being treated less frequently than white women
(19). Building on prior work evaluating differences in rt-PA by
race/ethnicity (20), we used the National (Nationwide) Inpatient
Sample (NIS), to explore differences in the utilization of rt-PA
at PSCs compared to non-PSCs, stratified by both sex and race/
ethnicity.

Demographic Variables

The NIS classifies sex as male or female. Race/ethnicity is reported
as non-Hispanic white, non-Hispanic black, Hispanic, Asian/
Pacific Islander, Native American, or other. Race and ethnicity are
not reported separately. Other patient-level variables included age,
year of discharge, expected primary payer (Medicaid, Medicare,
private, other), median household income in the patient’s ZIP
code, comorbid conditions (Table S2 in Supplementary Material)
(24), and an all-patient refined diagnosis related group (APRDRG) measure of the expected risk of inpatient mortality. The
APR-DRG uses diagnosis and procedure codes to estimate the
likelihood of dying during the hospitalization as minor, moderate, major, or extreme (25). The APR-DRG marker is not specific
to stroke and does not include a measure of stroke severity.
Hospital-level variables included geographic region (Northeast,
Midwest, South, West), rural or urban location, status as a teaching hospital (yes/no), and annual ischemic stroke case volume
(<100, 100–299, ≥300).

Statistical Analysis

The statistical approach for this study parallels prior work from
our group using the NIS to evaluate rt-PA use. Baseline characteristics were described for patients treated at PSCs and nonPSCs using measures of central tendency (means, medians) for
continuous variables and proportions for categorical variables.
Differences between the groups were evaluated using Student’s
t, Wilcoxon rank-sum, and χ2 tests, as appropriate. Patients were
stratified by sex, and then further stratified by race/ethnicity
within sex. A multivariate model was constructed to determine
independent associations including year of discharge, age, sex,
primary expected payer, median income by ZIP code, hospital
region, teaching status, urban/rural location, and ischemic stroke
admission volume, the 29 Elixhauser comorbid conditions, and
the APR-DRG measure of disease severity (20). Our analytic
models used NIS survey statistics and Taylor series estimation
to account for the survey design and clustering within hospitals.
The analysis was conducted using SAS-callable-SUDAAN version 11.0.1. As this was an exploratory analysis, no adjustments
were made for multiple comparisons (26). An alpha of 0.05 was
set as the level of significance.

MATERIALS AND METHODS
Study Design

A retrospective, cross-sectional analysis of data from the NIS
from 2004 to 2010 was conducted. As part of the Agency
for Healthcare Research and Quality’s Healthcare Cost and
Utilization Project, the NIS is the largest publicly available allpayer inpatient care database (21). This analysis limits the data
to 26 states that publicly identified both treating hospital and
patient race/ethnicity (Table S1 in Supplementary Material).
Data on PSC certification and date of initial certification for
PSCs was obtained via personal communication from TJC on
May 17th, 2011 (Jean Range, executive director of disease specific care, TJC, unpublished data, 2011). Methods for this work
have been previously reported (7, 20).
We identified patients aged ≥18 years who had a primary diagnosis of ischemic stroke defined by International Classification
of Diseases, 9th Revision (ICD-9) codes 433.x1, 434.x1, and 436.
The positive predictive value of these codes for identifying acute
ischemic stroke is greater than 85% (22). We excluded patients
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RESULTS
Between 2004 and 2010, acute ischemic stroke was the primary
diagnosis for 598,606 hospitalizations in the NIS. The inclusion/
exclusion criteria for the study population and the baseline
patient- and hospital-level characteristics stratified by PSC
status have been previously published (20). Table 1 describes
the patient- and hospital-level characteristics for the sample,
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A lower proportion of women than men received rt-PA at
both PSCs (6.8 vs. 7.5%, p < 0.001) and non-PSCs (2.3 vs. 2.8%,
p < 0.001). Figure 2 shows treatment rates stratified by sex and
race. A higher proportion of patients received rt-PA at PSCs in
all sex and race/ethnicity groups. The proportion of rt-PA treated
patients at PSCs ranged from 4.4% in black women to 8.1% in
white men. The proportion of rt-PA treated patients at non-PSCs
ranged from 1.9% for black women to 3.0% for white men.
In an unadjusted model, women were at lower odds of being
treated with rt-tPA compared to men at both PSCs and non-PSCs
(Table 2). After adjusting for year, age, primary expected payer,
median income quartiles by ZIP code, region, teaching hospital,
urban hospital location, annual ischemic stroke case volume, 29
AHRQ individual comorbidities, and APR-DRG risk of mortality, the odds of being treated with rt-PA remained significantly
lower for women regardless of presentation to a PSC (OR 0.87,
95% CI 0.81–0.94) or non-PSC (OR 0.88, 95% CI 0.0.82–0.94).
After stratifying by race, white women had significantly lower
odds of rt-tPA treatment in the adjusted model (Table 2). In the
multivariable model, sex did not modify the effect of PSC status
on rt-PA utilization (p-value for interaction = 0.58).

Table 1 | Patient and hospital characteristics stratified by sex.
Overall patient
population

Male patients
n = 141,841

Female patients
n = 162,311

n = 304,152

(46.6%)

(53.4%)

%

%

%

24.7

25.4

24.1

71.5
15.0
7.9
5.6

71.0
14.4
8.6
6.0

71.9
15.5
7.4
5.2

3.9
25.1
37.7
33.3

4.3
31.4
40.0
24.3

3.6
19.6
35.7
41.1

23.5
24.2
24.1
26.0
2.3

23.0
24.1
24.2
26.1
2.6

23.8
24.3
24.1
25.8
2.0

68.0
6.8
18.9
3.7
0.6
2.0

61.9
6.9
22.9
4.9
0.7
2.6

73.3
6.7
15.4
2.7
0.4
1.5

30.9
10.2
32.4
26.5
10.5
41.1

30.6
9.9
32.8
26.7
10.2
42.1

31.1
10.4
32.1
26.4
10.8
40.3

14.5
46.6
38.9

13.9
46.2
40.0

15.1
46.9
38.1

Evaluated at a primary
stroke centera
Race/ethnicitya
White
Black
Hispanic
Otherb
Agea
18–44
45–64
65–80
>80
Incomea,c
Lowest quartile
Second quartile
Third quartile
Highest quartile
Missing
Payment typea
Medicare
Medicaid
Private, incl. HMO
Self-pay
No charge
Other
Hospital regiond
Northeast
Midwest
South
West
Rural hospital locatione
Teaching hospitala
Ischemic stroke volumea
<100 (cases/year)
100–299 (cases/year)
≥300 (cases/year)

DISCUSSION
Our results illustrate that the relationship between PSC certification and rt-PA utilization is similar in men and women. PSCs
utilize rt-PA more than non-PSCs in both men and women,
regardless of race/ethnicity. However, our results also illustrate
that women are less likely to receive rt-PA than men at both PSCs
and non-PSCs. In absolute treatment proportions, black patients
are treated in lower proportions than other racial/ethnicity
groups, and black women are treated less than any other group;
however, the relative odds of treatment were lowest in white
women relative to white men.
Sex disparities in the treatment of stroke remain a concern,
particularly with the rise in incident stroke among women.
IV rt-PA is effective for both men and women, but women may
be even more likely to benefit from treatment than men (27, 28).
Among patients not treated with rt-PA, women may have worse
outcomes than men (29). It is therefore critical to ensure that
women with stroke who are eligible for rt-PA receive treatment.
PSCs administer more rt-PA than non-PSCs. This difference is
equally true in men and in women. As more PSCs become certified throughout the US and as a greater proportion of stroke
patients are evaluated at PSCs, IV rt-PA treatment in women
should continue to increase. However, a better understanding
of the drivers of sex differences in rt-PA treatment is needed
to maximize the population benefit of developing systems of
care and eliminate existing disparities. Identification of these
drivers is of particular importance considering the evidence
that rt-PA is associated with a greater improvement in stroke
symptoms for women than for men, with no differences in
adverse events after rt-PA administration between men and
women (30, 31).
Lower rt-PA treatment rates in women may be related to
patient factors. First, women tend to be older than men at the
time of stroke. Second, women tend to present with more severe

χ test between males and females significant, p < 0.001.
Other includes Asian/Pacific Islander, Native American, or other.
c
Median household income, by ZIP code.
d 2
χ test between males and females significant, p = 0.003.
e 2
χ test between males and females significant, p = 0.001.
a 2
b

stratified by sex. Overall, 53.4% of the patients were women.
Among women, 71.9% were white, 15.5% black, 7.4% Hispanic,
and 5.2% were in other categories (e.g., Asian/Pacific Islander,
Native American, other). Among men, 71.0% were white, 14.4%
were black, 8.6% Hispanic, and 6.0% other. There were 75,160
(24.7%) patients evaluated at a PSC, and 228,992 (75.3%) evaluated at a non-PSC.
The proportion of patients evaluated at a PSC increased over
time with similar proportions for men and women. The proportion of racial/ethnicity groups presenting to a PSC stratified by
sex increased over time (Figure 1). A little over half of the patients
evaluated at PSCs were women (53.8%), with 71.5% of white,
14.5% of black, 8.8% of Hispanic, and 5.3% of other patients
evaluated at a PSC.
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Figure 1 | Proportion of patients presenting to a primary stroke center over time, stratified by sex and then by race/ethnicity.

Figure 2 | Proportion of men and women treated with rt-PA stratified by race/ethnicity and primary stroke center (PSC) versus non-PSC.

strokes (32). Third, knowledge of the signs and symptoms of
stroke may be lower in women (14). This could potentially
contribute to a delay in emergency department presentation,
thereby preventing women from being treated if presentation is
outside of the treatment time window (33). Unfortunately, the

Frontiers in Neurology | www.frontiersin.org

National Inpatient Sample does not contain the granular clinical
data necessary to investigate these possibilities. More research is
needed to determine why women are treated at a lower proportion than men so that sex disparities in acute stroke therapies can
be eliminated.
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Table 2 | Odds of being treated with rt-PA for women, relative to men, at non-PSCs and primary stroke centers (PSCs), stratified by race/ethnicity.
Sex

Non-PSC

PSC

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

0.83 (0.78–0.88)

0.88 (0.82–0.94)

0.88 (0.83–0.93)

0.87 (0.81–0.94)

0.80 (0.75–0.85)
0.90 (0.78–1.04)
0.92 (0.74–1.12)
1.04 (0.80–1.35)

0.84 (0.78–0.90)
0.99 (0.82–1.20)
1.04 (0.82–1.33)
1.09 (0.77–1.53)

0.88 (0.82–0.94)
0.84 (0.72–0.99)
0.87 (0.66–1.14)
1.00 (0.81–1.24)

0.85 (0.78–0.93)
0.96 (0.77–1.21)
0.85 (0.61–1.18)
0.91 (0.67–1.25)

Overall
By race/ethnicity
White
Black
Hispanic
Other

Adjusted for (where applicable): year, age, sex, primary expected payer, median income quartiles by ZIP, region, teaching hospital, urban hospital location, annual ischemic stroke
case volume, 29 AHRQ individual comorbidities, all-patient refined diagnosis related group risk of mortality (minor, moderate, major, and extreme likelihoods of dying).

Black women have the lowest proportion of rt-PA treatment,
regardless of PSC status of the treating hospital. This finding supports prior data from two academic medical centers, which also
found that black women were treated less frequently with rt-PA.
In prior studies, black women were more likely to have delayed
presentation, and once time from onset was accounted for, the sex
and race disparity in rt-PA treatment no longer remained (19).
It is possible that differences in time to presentation are responsible for the findings in the present study, but as noted above,
symptom duration is not available in the NIS.
This study has limitations similar to prior work evaluating
rt-PA use in the NIS (7, 20). As this study relies on administrative
claims data defined by ICD-9 codes, we were unable to determine
if there were differences in rt-PA eligibility, stroke severity, or
time to presentation. We do not have information on functional
outcomes after rt-PA in this dataset and cannot assess sex differences in outcomes. States that do not provide data on hospital
identity or race were excluded, including a few with large minority populations, such as Georgia and Texas. In spite of this, the 26
states that provided data cover approximately 50% of the Hispanic
and black population in the United States (34, 35). The definition
of PSCs by TJC certification does not recognize other national
or state-based certifications or identify hospitals that participate
in national stroke care improvement programs, such as Get with
the Guidelines. Misclassification of these hospitals as non-stroke
centers would likely bias the results toward the null and would not
change the observed disparities. The use of the ICD-9 procedure
code 99.10 to define rt-PA may underestimate rt-PA use. This has
the potential to introduce bias if coding varies between PSCs and
non-PSCs or, less likely, between women and men (36). Finally,
we are unable to investigate “drip and ship” cases. This could lead
to underestimation of rt-PA utilization at non-PSCs.

to rt-PA underutilization. The increased utilization of rt-PA at
PSCs is consistent between men and women and stable across
racial and ethnic groups. Considering women may benefit from
rt-PA utilization more than men, the disparity in utilization is
concerning. Further research is needed to investigate what factors
are contributing to this sex disparity.
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